Postexposure prophylaxis of H1N1 with oseltamivir in a newly transplanted kidney recipient receiving intense immunosuppressive therapy

Transplant Proc. 2009 Dec;41(10):4411-3. doi: 10.1016/j.transproceed.2009.09.052.

Abstract

Solid organ transplant recipients undergoing immunosuppressive therapy are considered to be at high risk for serious infectious complications. Recently in the United States, a pandemic of H1N1 flu infection has been reported with serious complications. We describe H1N1 infection in a living kidney donor and the 42-year-old kidney transplant recipient exposed to this kidney donor and undergoing intense immunosuppressive therapy. Postexposure prophylaxis with oseltamivir was effective to prevent H1N1 influenza A virus in a donor and a recipient.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antilymphocyte Serum / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Cesarean Section
  • Female
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Influenza A Virus, H1N1 Subtype / drug effects*
  • Influenza, Human / prevention & control*
  • Influenza, Human / transmission
  • Kidney Failure, Chronic / surgery*
  • Kidney Transplantation / physiology*
  • Living Donors
  • Medical History Taking
  • Oseltamivir / therapeutic use*
  • Pregnancy
  • Renal Dialysis
  • Risk Factors
  • Rituximab
  • Siblings
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antilymphocyte Serum
  • Antiviral Agents
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Oseltamivir
  • Rituximab